The maximum dosage of semaglutide: how the ceiling works and what shapes it

Why the maximum semaglutide dosage is a ceiling, not a target

When patients ask about the max semaglutide dosage, they often expect a single number. In practice, the ceiling depends on which formulation you are taking and, crucially, how well you tolerate the journey up to it. The Wegovy injection starts at 0.25 mg weekly (a dose chosen almost entirely for tolerability, not effect) and climbs through 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, with roughly four weeks at each level. That 2.4 mg figure was the standard maintenance ceiling from Wegovy's original UK approval.

In January 2026 the MHRA took a further step, approving a 7.2 mg maintenance dose (initially delivered across three 2.4 mg pens weekly) and then, on 14 April 2026, approving a dedicated single-dose 7.2 mg pen for adults with a BMI of 30 or above. Trials reported an average weight loss of around 20.7% over 72 weeks at 7.2 mg, which narrows the gap considerably with the tirzepatide trial data. If you want a fuller breakdown of all the dose steps available, the Wegovy doses guide covers each one in detail.

For the tablet, the ceiling is 25 mg daily. The schedule is 1.5 mg, then 4 mg, then 9 mg, then 25 mg, a minimum of one month at each rung before moving up. The NHS medicines guidance for semaglutide, available on the NHS tirzepatide and semaglutide medicines page, outlines this schedule at a patient-facing level.

What stops someone reaching the licensed maximum?

Semaglutide's most common side effects are gastrointestinal: nausea, loose stools, vomiting, indigestion. They tend to peak after a dose increase and often settle within a week or two. But if side effects at a given dose are severe or persistent, the right clinical decision is usually to stay at that level longer rather than push to the next one, or even to step back temporarily. The licensed maximum is a ceiling the medicine can reach safely in the studied population; it is not a threshold that everyone needs to cross.

Dose progression is also not automatic. At nume, sorry, at nume, every repeat order goes through clinical re-review before a new dose is issued. A prescriber looks at how your body has responded, your reported side effects and, for dose increases, the evidence you provide of your current weight. That process exists precisely so the maximum semaglutide dosage is reached sensibly rather than chased as a goal in itself.

People who have already been on weekly semaglutide injections at 2.4 mg and are switching to the tablet can, in some cases, move directly to the 25 mg tablet, but that transition is subject to clinical assessment, not a blanket rule. Details of the full semaglutide dosage schedule show how injection and tablet pathways compare.

Does a higher dose always mean better results?

Not necessarily, and this is the part of the question worth sitting with. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks on the 2.4 mg weekly injection alongside lifestyle changes. The 7.2 mg data reported higher average losses. But individual response varies: genetics, baseline weight, diet, activity and adherence all shape outcomes in ways that a dose number alone cannot predict.

Some people stabilise well below the maximum and maintain weight loss without titrating higher. Others need the top dose to see meaningful change. Your prescriber's job is to find the dose that balances effect and tolerability for you specifically, not to push the number as high as the licence allows.

One practical point on routine: the tablet is taken first thing in the morning on an empty stomach with a small glass of water, then nothing else for at least 30 minutes, including coffee. Keeping a glass of water on the kitchen counter next to the kettle, rather than in the fridge, is a small habit that makes the timing straightforward. The injection, by contrast, is stored refrigerated; a semaglutide dosage chart laying out timing and storage side by side can be a useful reference when you first start.

On costs, private treatment pricing depends on the dose and formulation, you can see how that shapes up on the Wegovy pricing page.

When to talk to a prescriber about your dose

If you are already on semaglutide and wondering whether to push toward the maximum, the right conversation is with your prescriber rather than a dosing chart. The questions that shape that decision include: How much weight have you lost so far? How well are you tolerating the current dose? Have you reached a plateau? Are you experiencing side effects that make an increase inadvisable right now?

The full Wegovy guide covers the clinical picture from eligibility through to how prescribers think about maintenance, and our guide to the max dose of semaglutide goes into further detail on how that upper limit is determined and when reaching it makes clinical sense. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the place to report any side effect you experience, including at the maximum dose, it is there for patients as much as for clinicians.

If you have not yet started and are weighing up whether semaglutide is appropriate for you, a free consultation with one of our prescribers is the practical next step. Check your eligibility and a GPhC-registered prescriber will review your details the same day.